Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05656560 · ClinicalTrials.gov registry record · NA

Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges R01 Trial

A NA study of Polypharmacy, sponsored by Northwestern University.

Active
Registry status
NA
Development phase
786
Enrollment target
2
Study locations

NCT05656560: Active NA study of Polypharmacy, sponsored by Northwestern University.

NCT05656560 is a NA study of Polypharmacy that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 786 participants, below the 1,459-participant average among 11 other Polypharmacy trials with a reported enrollment target (46% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05656560, a NA study of Polypharmacy, is active but no longer recruiting, sponsored by Northwestern University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
786 participants
Enrollment target
2
Study locations

Study Summary

High-risk polypharmacy is common among older adults in the United States, is particularly dangerous for individuals with dementia or cognitive impairment, and is associated with harms such as adverse drug reactions, falls, and higher costs of care. This project aims to test in a pragmatic clinic-randomized controlled trial two electronic health record-based behavioral economic nudges to help clinicians reduce high-risk polypharmacy among their older adult patients and in the subgroup with dementia or cognitive impairment. The main questions this trial aims to answer are: Aim 1: To evaluate the effects of an EHR-based commitment nudge, a justification nudge, and the combination of both nudges on a composite measure of high-risk polypharmacy via a pragmatic randomized controlled trial. The investigators will use cluster randomization in which primary care clinics are randomized to receive 0, 1, or 2 nudges using a factorial design. The nudges will run for 18 months, followed by 12 months of observation to assess persistence of effects. Aim 2: To qualitatively and quantitatively assess clinician experiences with the EHR-based nudges, including their acceptability and effects on workflow. At the conclusion of the intervention period, the investigators will perform semi-structured interviews and field a clinician survey.

Primary Outcome

The composite of the 7 high-risk polypharmacy measures (Secondary outcomes #6-12)

Conditions Studied

Interventions

  • BEHAVIORAL Clinical decision support (CDS)-Commitment nudge
  • OTHER Clinician education
  • BEHAVIORAL Clinical decision support (CDS)-Justification nudge

Study Locations (2)

Illinois

  • Northwestern Medicine - Chicago

Pennsylvania

  • UPMC - Pittsburgh

Trial Details

FieldValue
Enrollment Target 786 participants
Start Date 2023-06-08
Est. Completion 2026-05-31
Phase NA
Northwestern University

1,209 total trials

What the registry record for NCT05656560 still lists

NCT05656560 is an interventional study that assigns participants to a tested intervention. The registered 786 participants enrollment target is mid-sized for trials with a published cap, below the 1,459-participant average among 11 other Polypharmacy trials with a reported enrollment target (46% lower).

The record links to 1 condition, with Polypharmacy appearing as the primary indexed condition, and to 3 interventions - of which Clinical decision support (CDS)-Commitment nudge is the first listed.

NCT05656560 reports a single indexed study location in Illinois, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05656560 about?

NCT05656560 is a clinical study titled "Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges R01 Trial". High-risk polypharmacy is common among older adults in the United States, is particularly dangerous for individuals with dementia or cognitive impairment, and is associated with harms such as adverse drug reactions, falls, and higher costs of care. This project aims to test in a pragmatic clinic-ran...

What is the current status of trial NCT05656560?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 786 participants. The study started on 2023-06-08. Estimated completion is 2026-05-31.

What conditions does trial NCT05656560 study?

This clinical trial studies the following conditions: Polypharmacy.

What interventions are being tested in trial NCT05656560?

The interventions under investigation include: Clinical decision support (CDS)-Commitment nudge (BEHAVIORAL), Clinician education (OTHER), Clinical decision support (CDS)-Justification nudge (BEHAVIORAL).

Who is sponsoring clinical trial NCT05656560?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05656560 being conducted?

This trial has 2 study locations across Illinois, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Polypharmacy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05656560's enrollment target sits among peer trials

786 6th of 11 higher than 6 of 11 other Polypharmacy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Polypharmacy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07276724 · 786 participants · Phase 3

    A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

  • NCT07359846 · 786 participants · Phase 3

    A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)

  • NCT06488781 · 787 participants · Phase 2

    Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0

  • NCT06876649 · 787 participants · Phase 4

    A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05656560, the US trial registry maintained by the National Library of Medicine. NCT05656560 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.